CNBC’s David Faber and Carl Icahn, chairman, Icahn Enterprises LP (NASDAQ:IEP), discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman’s recent efforts to partner with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and acquire Allergan, Inc. (NYSE:AGN).
Carl Icahn: We see things boards don’t
One Of The Original Quants Has Still Not Lost His Touch With A 121% Return In 2020: In-Depth Profile Of Robert Zuccaro
Robert Zuccaro has been using quantitative investing strategies since before quant funds existed. In fact, he started one of the earliest quant funds at Axe-Houghton in 1978, 10 years before Morgan Stanley introduced its first quant fund. Q4 2020 hedge fund letters, conferences and more Zuccaro has been researching the correlation between earnings growth and Read More